QuidelOrtho Corporation Common Stock (QDEL) — Analysis Summary
QuidelOrtho Corporation Common Stock (QDEL) has a market cap of $908.62M with year-over-year revenue growth of -1.9%. Net margin stands at -41.5%. The stock trades at a P/E ratio of -0.9.
Key Takeaways
- Revenue changed -1.9% year-over-year
- Net margin of -41.5%
- P/E ratio of -0.9
Compared to other companies in the IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES sector, QDEL posted revenue growth of -1.9% and trades at a P/E of -0.9.
QuidelOrtho Corporation Common Stock (QDEL)
PREVIOUS CLOSE 2026-10-12 · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Interest coverage at -4.1x — earnings do not cover interest payments
Operating margin at -30.8% — material operating losses
Net margin at -39.2% — significant losses
The latest filing shows negative free cash flow.
QuidelOrtho Corp is engaged in the development, manufacturing, and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry, and transfusion medicine, which helps clinicians and patients to make decisions across the globe. Geographically, the company has its presence in North America, EMEA, China, and Other countries. It generates the majority of its revenue from North America.
Sector
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Employees
6,500
Headquarters
SAN DIEGO, CA
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.